← All trials
NCT05596045
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 28, 2022
- Primary completion
- Mar 8, 2023
- Completion date
- Oct 9, 2023
- First posted
- Oct 27, 2022
- Last posted
- Oct 31, 2022
- Enrollment
- 32
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ascletis Pharmaceuticals Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.